GGrantIndex
Sort

89,613 grants matching depression

NAAA Inhibition for Pain and Inflammation

$983,494
Edward Paul Monaghan · Neokera, Llc · R44 · FY2018 · NS

Indiana PREGMED

$983,372
David Alastair Flockhart · Indiana University Indianapolis · U10 · FY2010 · HD

Preclinical Alzheimer Disease and Driving

$983,337
Catherine M Roe · Washington University · R01 · FY2017 · AG

Parent Engagement and Child Learning Birth to Five

$983,321
Susan M Sheridan · University Of Nebraska Lincoln · R01 · FY2007 · HD

Stream Dx: Point of Care Cellular Enabled IoT Communication Hub for Improved Diagnosis, Monitoring, and Post-Treatment Evaluation of LUTS

$983,074
Scott Bradford McClellan · Stream Dx, Inc. · R44 · FY2021 · DK

Operations, Clinical Assessments and Adminstrative Core

$983,062
Helen S Mayberg · Emory University · P50 · FY2009 · MH

Phosphodiesterase-4B (PDE4B) Inhibitors for Psychiatric Disease

$982,403
Mark E Gurney · Tetra Discovery Partners, Inc. · R44 · FY2018 · MH

CLINICAL EPIDEMIOLOGY OF DEMENTIA IN GENERAL PRACTICE

$982,402
University Of Pittsburgh At Pittsburgh · R01 · FY2003 · AG

Developing Infrastructure for Patient-Centered Outcomes Research at Denver Health

$982,012
Edward Havranek · Denver Health And Hospital Authority · R24 · FY2017 · HS

Developing novel technologies to monitor nociception and opioid administration during surgery and general anesthesia in order to minimize post-operative opioid requirements

$981,839
Tuan Le Mau · Pascall Systems, Incorporated · R42 · FY2023 · DA

Leveraging Protein Kinase G-1 Nanodomain Control and Molecular Targeting to Enhance its Therapeutic Use Against Myocardial Disease

$981,748
David Alan Kass · Johns Hopkins University · R35 · FY2021 · HL

Leveraging Protein Kinase G-1 Nanodomain Control and Molecular Targeting to Enhance its Therapeutic Use Against Myocardial Disease

$981,748
David Alan Kass · Johns Hopkins University · R35 · FY2022 · HL

Leveraging Protein Kinase G-1 Nanodomain Control and Molecular Targeting to Enhance its Therapeutic Use Against Myocardial Disease

$981,748
David Alan Kass · Johns Hopkins University · R35 · FY2019 · HL

Leveraging Protein Kinase G-1 Nanodomain Control and Molecular Targeting to Enhance its Therapeutic Use Against Myocardial Disease

$981,748
David Alan Kass · Johns Hopkins University · R35 · FY2020 · HL

Aligning facility leadership and climate to advance mental health services integration in Malawi

$981,668
Brian W Pence · Univ Of North Carolina Chapel Hill · R01 · FY2023 · MH

Digital multidomain lifestyle intervention to address cognitive health and modifiable risk factors for Alzheimer's disease

$981,630
Jordan Glenn · Neurotrack Technologies, Inc. · R44 · FY2022 · AG

Neuropeptides and Carboxypeptidase E/ Neurotrophic Factor-1 in Neural and Cognitive Functions

$981,601
Yoke Peng Loh · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2018 · HD

CBASP Augmentation for Treatment of Chronic Depression

$981,549
University Of Pittsburgh At Pittsburgh · U01 · FY2004 · MH

Leveraging Protein Kinase G-1 Nanodomain Control and Molecular Targeting to Enhance its Therapeutic Use Against Myocardial Disease

$981,073
David Alan Kass · Johns Hopkins University · R35 · FY2018 · HL

Mindfulness-based Cognitive Coping Mobile App Intervention for caregivers of individuals with Alzheimer's Disease

$980,975
Bruno Kajiyama · Photozig, Inc. · R44 · FY2021 · AG

NCMHD-Research Center of Excellence at the University of Pittsburgh

$980,936
Stephen B. Thomas · University Of Pittsburgh At Pittsburgh · P60 · FY2008 · MD

The Proactive Screening and diagnosis of mild cognitive impairment and depression in patients aged 65 and over: An Implementation Study

$980,904
Shenly Glenn · Miro Health Inc · R44 · FY2023 · AG

Pre-Operative PSG Assessment of Cardiac Surgery Inpatients

$980,873
Hani Akram Kayyali · Cleveland Medical Devices, Inc. · R44 · FY2006 · NS

Enhanced supercooling for extending non-freezing preservation in preclinical porcine and human donor livers

$980,782
Michael John Taylor · Sylvatica Biotech, Inc. · R44 · FY2025 · DK

Efficacy of CBT for Adherence and Depression in HIV Care Settings

$980,660
Steven A Safren · Massachusetts General Hospital · R01 · FY2011 · MH